DISCOVER CKD
Research type
Research Study
Full title
An observational study collecting real-world data on patients with chronic kidney disease to assess: early treatment experience, treatment patterns, treatment effectiveness, patient outcomes and patient quality of life through prospective and retrospective data capture.
IRAS ID
269711
Contact name
Glen James
Contact email
Sponsor organisation
AstraZeneca
Clinicaltrials.gov Identifier
243962, Parexel ref
Duration of Study in the UK
4 years, 3 months, 17 days
Research summary
Chronic kidney disease (CKD) is a global health burden associated with adverse clinical consequences, some of which include cardiovascular disease, hyperkalaemia (HK), anaemia, hyperphosphataemia, increased cardiovascular mortality, oedema, and progression to end stage renal disease (ESRD) resulting in high healthcare costs and reduced health-related quality of life (HRQoL).
The high prevalence and the extensive existing evidence that intervention is effective in reducing cardiovascular events demonstrates a need for initiatives that will slow the progression to ESRD and reduce cardiovascular-related events in CKD patients
Currently, real-world data on the patient journey, including treatment patterns, HRQoL, and diet in CKD patients with anaemia or HK are limited. There is a need to fill this gap as well as understand the early experience of Roxa (roxadustat), Lokelma (sodium zirconium cyclosilicate), and Forxiga (dapagliflozin) in a real-world CKD setting (including patient characteristics and changes in patient reported information before and after therapy initiation).
REC name
Yorkshire & The Humber - South Yorkshire Research Ethics Committee
REC reference
19/YH/0357
Date of REC Opinion
16 Oct 2019
REC opinion
Favourable Opinion